Gts Securities LLC Cassava Sciences Inc Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$9.57 - $35.08 $780,912 - $2.86 Million	81,600 Added 135.77%	141,700 $4.17 Million
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $29,640 - $62,664	2,400 Added 4.16%	60,100 $742,000
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $1.16 Million - $1.66 Million	-62,900 Reduced 52.16%	57,700 $1.17 Million
Q4 2023 Feb 14, 2024	SELL	$12.64 - $30.11 $308,416 - $734,684	-24,400 Reduced 16.83%	120,600 $2.71 Million
Q3 2023 Nov 15, 2023	BUY	$16.64 - $25.32 $2.41 Million - $3.67 Million	145,000 New	145,000 $2.41 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $154M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.